Floatz logo

bz019

Transformed Lymphoma

Institute of Hematology & Blood Diseases Hospital, ChinaCell therapyPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

289 Active assets in the Transformed Lymphoma cohort.

Asset / SponsorPhaseRating
VINBLASTINE
Intensity Therapeutics, Inc.
Phase 4BBB
CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE
The Lymphoma Academic Research Organisation
Phase 4BBB
BLEOMYCIN
Shandong Provincial Hospital
Phase 4BB
VINCRISTINE SULFATE
Inhye Ahn
Phase 3BB
(+)-VINCRISTINE
Beth Israel Deaconess Medical Center
Phase 4BB

View all 50 →

Same molecule, other indications

bz019 is also rated in:

large B-cell lymphomaDormant
CCC
Indicative ·
55 / 100
View asset →
primary mediastinal large B-cell lymphomaDormant
CC
Indicative ·
44 / 100
View asset →
diffuse large B-cell lymphomaDormant
CC
Indicative ·
42 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →